Dren Bio Strengthens Leadership Team with Appointment of Amit Mehta, Ph.D., as Chief Operating Officer and Chief Business Officer
Dren Bio, Inc. (“Dren Bio” or the “Company”) a clinical-stage biopharmaceutical company developing antibody therapeutics for cancer, autoimmune and other serious diseases, today announced the expansion of its leadership team with the appointment of Amit Mehta, Ph.D., as the Company’s Chief Operating Officer and Chief Business Officer.
- Dren Bio, Inc. (“Dren Bio” or the “Company”) a clinical-stage biopharmaceutical company developing antibody therapeutics for cancer, autoimmune and other serious diseases, today announced the expansion of its leadership team with the appointment of Amit Mehta, Ph.D., as the Company’s Chief Operating Officer and Chief Business Officer.
- Dr. Mehta will be responsible for business development efforts, corporate strategy and leading the operational advancement and expansion of Dren Bio’s pipeline.
- During his 18-year tenure at Genentech, Dr. Mehta held roles of increasing responsibility that spanned process development, manufacturing, strategy and business development.
- “We are thrilled to welcome Amit as the newest member of Dren Bio’s leadership team,” said Nenad Tomasevic, Ph.D., Chief Executive Officer of Dren Bio.